ERBB2 and breast cancer: The FDA has approved the combination of pan-PI3K inhibitors with fulvestrant for ER+ BC; however, preclinical studies have demonstrated toxicity when targeting the PI3K pathway in conjunction with anti-HER2 inhibitors.